Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma

Ladetto, Marco; Pagliano, G; Ferrero, Simone; Cavallo, Federica; Drandi, Daniela; Santo, Loredana; Crippa, Claudia; De Rosa, Luca; Pregno, Patrizia; Grasso, Mariella; Marina Liberati, Anna; Caravita, Tommaso; Pisani, Francesco; Guglielmelli, Tommasina; Callea, Vincenzo; Musto, Pellegrino; Cangialosi, Clotilde; Passera, Roberto; Boccadoro, Mario; Palumbo, Antonio

doi:10.1200/jco.2009.23.7172

Public

Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma

Published in Journal of Clinical Oncology • Mar 22, 2010

Authors:

Marco Ladetto

G Pagliano

Simone Ferrero

Abstract

PURPOSE We investigated the effect on minimal residual disease, by qualitative and real-time quantitative polymerase chain reaction (RQ-PCR), of a consolidation regimen that included bortezomib, thalidomide, and dexamethasone (VTD) in patients with multiple myeloma (MM) responding to autologous stem...

Subject

Medicine

Thalidomide

Dexamethasone

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!